Altimmune Announces Third Quarter 2026 Financial Results and Business Update
Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD hi
Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD hi